AAP
LAB icon

Arax Advisory Partners’s Standard BioTools LAB Stock Holding History

Arax Advisory Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.63K Buy
11,709
+10,708
+1,070% +$10.1K ﹤0.01% 4353
2026
Q1 		$920 Buy
1,001
+989
+8,242% +$1.2K ﹤0.01% 3318
2025
Q4 		$15 Sell
12
-2,737
-100% -$3.68K ﹤0.01% 4041
2025
Q3 		$3.57K Buy
+2,749
New +$3.6K ﹤0.01% 2961

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Arax Advisory Partners's LAB Position: Q2 2026 in Review

Arax Advisory Partners increased its Standard BioTools (LAB) stake by 1,070% in Q2 2026, buying an estimated $10.1K and bringing the position to 11,709 shares worth $9.63K. The position accounts for ﹤0.01% of the portfolio, ranked #4353.

Arax Advisory Partners first reported a position in LAB in Q3 2025 and has held it in 4 quarters since. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Arax Advisory Partners held 11,709 shares of Standard BioTools worth $9.63K as of Q2 2026.
  • Arax Advisory Partners bought 10,708 Standard BioTools shares in Q2 2026, an estimated $10.1K.
  • Standard BioTools made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4353 holding.
  • Arax Advisory Partners first reported a position in Standard BioTools in Q3 2025 and has held it in 4 quarters since.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.